Embla Medical hf. (OSSUY) Q2 2026 Earnings Call Transcript

Sveinn Sölvason President & CEO Thank you very much. Good morning, and welcome to Embla Medical's conference call to review our second quarter 2026 results. I'm Sveinn Solvason, President and CEO of Embla Medical. Joining me today are our Chief Financial Officer, Arna Sveinsdottir; and our Head of Investor Relations, Klaus Sindahl. Presentation will approximately 15 minutes, followed by a Q&A session. If you please turn to the next slide. The first half of 2026 was strong. We delivered good organic growth and increased profitability and solid free cash flow. Sales in the second quarter were $259 million, corresponding to 11% reported growth and 6% organic growth. Prosthetics and neuro orthotics continued to do very well with double-digit growth in the quarter. This was driven by strong execution, good volume growth in mainly EMEA and APAC and contributions from recently launched products. Bracing and Supports grew at a more modest pace and patient care declined, but we're seeing very encouraging progress. EBITDA margin was strong at 22% for the quarter. This was supported by the good performance in prosthetics